ERBB2 and breast carcinoma: These guidelines are consistent with the observation in our study that patients who continued to receive Trastuzumab treatment along with these cardio-protective agents had significantly lower rates of severe cardiac adverse events without any increase in cardiac deaths, thus justifying the concept of permissive cardiotoxicity in HER2-positive breast cancer management [41, 42].